BioLine Rx (BioLine Rx) Float Percentage Of Total Shares Outstanding : 0.00% (As of Apr. 27, 2024)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BioLine Rx's float shares is 0.00 Mil. BioLine Rx's total shares outstanding is 79.94 Mil. BioLine Rx's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BioLine Rx's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BioLine Rx's Institutional Ownership is 0.15%.

BioLine Rx Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BioLine Rx's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	79.94
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.